Esaxerenone (CAS 1632006-28-0) is a GMP-compliant, high-purity active pharmaceutical ingredient (API), a highly selective non-steroidal mineralocorticoid receptor antagonist (MRA). Approved in Japan for primary hypertension and type 2 diabetic nephropathy treatment, it delivers robust antihypertensive efficacy with reduced endocrine side effects, fully complying with ICH, JP and USP pharmacopoeia standards.

Galantamine Hydrobromide (CAS 1953-04-4) is a GMP-compliant, high-purity active pharmaceutical ingredient (API), a reversible, centrally selective acetylcholinesterase inhibitor. Globally approved for mild-to-moderate Alzheimer's dementia cognitive improvement, it fully meets USP/EP/CP and ICH international quality standards.

Lemborexant (CAS 1369764-02-2) is a high-purity, GMP-compliant dual orexin receptor antagonist (DORA) API. It is clinically indicated for the treatment of insomnia disorder in adults, improving sleep onset and maintenance with favorable next‑day residual effects. It complies with ICH, USP and EP pharmacopoeial standards.

Mirogabalin Besylate (CAS 1138245-21-2) is a GMP-compliant, high-purity API, a selective α2δ-1 ligand of voltage-gated calcium channels. Approved for peripheral neuropathic pain (diabetic peripheral neuropathic pain & postherpetic neuralgia), it delivers sustained analgesia with favorable CNS safety, meeting ICH, JP, and USP pharmacopoeial standards.

Olmesartan Medoxomil (CAS 144689-63-4) is a high-purity, GMP-grade angiotensin II receptor antagonist (ARB) API. It is indicated for the treatment of hypertension, providing long-lasting blood pressure control with good tolerability. It meets USP, EP, and ICH quality standards, suitable for pharmaceutical formulation development and commercial production.

Rimegepant Sulfate (CAS 1374024-48-2) is a high-purity, GMP-compliant active pharmaceutical ingredient. As a potent oral CGRP receptor antagonist, it is indicated for both acute treatment and preventive management of migraine in adults. It meets ICH, USP and EP pharmacopoeial standards, suitable for pharmaceutical R&D and commercial tablet formulation production.

Terbinafine Hydrochloride (CAS 78628-80-5) is a high-purity, GMP-compliant allylamine antifungal API. It blocks fungal squalene epoxidase to achieve strong fungicidal activity, mainly used for treating onychomycosis, dermatophytosis and superficial fungal infections. It complies with USP, EP and ICH pharmacopoeial standards, ideal for pharmaceutical formulation manufacturing.

Tranexamic Acid (CAS 1197-18-8) is a high-purity, GMP-compliant antifibrinolytic API. It inhibits plasminogen activation to control excessive bleeding, widely used for surgical hemostasis, menorrhagia, and hemorrhagic disorders. It meets USP, EP and ICH pharmacopoeial standards and is suitable for oral, injectable and topical pharmaceutical formulations.

Upadacitinib (CAS 2050057-56-0) is a high-purity, GMP-compliant API, a potent and selective JAK1 inhibitor (ABT-494). It treats rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis and other autoimmune diseases. Meeting USP, EP and ICH standards, it's ideal for oral extended-release tablet formulation development and commercial production

Vibegron (CAS 1190389-15-1) is a high-purity, GMP-compliant selective β3-adrenoceptor agonist API. It is clinically used for overactive bladder (OAB) to relieve urinary urgency, frequency and urge incontinence, with good cardiovascular safety profile. It conforms to USP, EP and ICH quality standards, suitable for oral pharmaceutical formulation R&D and commercial manufacturing.

Diquafosol Tetrasodium (CAS: 211427-08-6) is a GMP-compliant, high-purity selective P2Y2 purinergic receptor agonist API. It promotes tear and mucin secretion to repair ocular surface damage, approved for dry eye disease treatment. It fully meets ICH, JP, USP and EP pharmacopoeial standards, ideal for ophthalmic eye drop formulation R&D and commercial manufacturing.

Tazobactam Acid (CAS 89786-04-9) is a GMP-compliant, high-purity β-lactamase inhibitor active pharmaceutical ingredient (API). It irreversibly inactivates bacterial β-lactamases, widely used in combination with β-lactam antibiotics to combat drug-resistant gram-negative bacterial infections. It fully meets USP, EP and ICH international quality standards for pharmaceutical formulation manufacturing